looked at the intratumoral expression of various biologic markers that may be useful for the treatment of resectable non-small-cell lung cancers ... They also studied tumor proliferation rates ...

Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed of small, ovoid cells with ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Small cell lung cancer (SCLC) is one of the hardest types ... Finally, the team looked at molecular markers of increased electrical activity in a cohort of people with SCLC, finding that these ...

Small cell lung cancer accounts for 10–15% of all lung ... Survival rates are generalized markers that indicate the likelihood that a person will live after a set period of time.

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more ...

A recent study has shown that analysis of ctDNA methylation can aid the early diagnosis of non-small cell lung cancer ... methylated markers specific to lung cancer. Of the 276 predicted markers ...

It works by presenting the immune system with tumour markers from non-small cell lung cancer, the most common form of the disease, to prime the body to fight cancer cells expressing these markers.

Stage 4 non-small cell lung cancer (NSCLC) is the most advanced form of the condition and can be challenging to treat. Treatments include chemotherapy, surgery, immunotherapy, and radiotherapy.

The poster presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung ...

Lung cancer is by far the most lethal form of cancer in the U.S., accounting for about 1 in 5 of all cancer deaths.

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...